WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations with its "follow and win the molecule" and global dual sourcing strategies.

Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9 million ...

SHANGHAI, March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has ...

We have raised our fair value estimate for narrow-moat-rated WuXi Biologics to HKD 26.60 per share from HKD 24.60 following better-than-expected 2024 results and strong guidance for 2025.

Talents People are WuXi Biologics' greatest assets. As of December 31, 2024, the Group's total employee count reached 12,575, including 4,383 scientists, with a key talent retention rate of 95.8%. The ...

HONG KONG, March 25, 2025 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269), a leading global Contract Research, Development and Manufacturing ...

WuXi AppTec (Shanghai, China) has sold off two US/UK businesses in February and March, it revealed in its annual results on 18 March 2025. The Chinese contract research, development, and ...

Talents People are WuXi Biologics' greatest assets. As of December 31, 2024, the Group's total employee count reached 12,575, including 4,383 scientists, with a key talent retention rate of 95.8%.

WuXi Biologics is a leading global CRDMO, with the R represented by our premium-quality CRO Services. With expertise in diverse drug modalities, we deliver comprehensive research services, including ...

and now WuXi Biologics, which was added in the latest draft, according to a Reuters report. It would prohibit the purchase of equipment or contracting of servicers from the companies, which make a ...